Strategic Execution Partner

Boardroom strategy that actually lands in operations.

Lakeland Strategic Partners helps healthcare and medtech organizations accelerate commercialization, strengthen operating performance, and scale with discipline. We bridge clinical authority, financial rigor, and execution systems that move from strategy to measurable results.

0

C-suite operators and physician leaders

0

Years of senior operations track record represented in leadership

0

Execution phases from assessment through scale

Who We Are

Operators first. Advisors second.

We are not a slide-only advisory firm. Lakeland deploys implementation-grade strategy for growth-stage and transformation-stage businesses that cannot afford execution drift.

Our leadership bench includes physician executives, commercialization operators, and transformation leaders with direct experience in clinical adoption, revenue-cycle optimization, and platform scale-up.

What We Do

Execution engines for high-stakes growth.

Commercialization Architecture

Market entry strategy, channel sequencing, pricing discipline, and launch governance designed for measurable adoption.

Clinical Adoption Systems

KOL activation, value-analysis alignment, outcomes instrumentation, and clinical-commercial integration that de-risks scale.

Operational Transformation

End-to-end process redesign, ERP/CRM workflow modernization, and performance management tied to margin and throughput.

Investment Readiness

Strategic diligence support, value-creation thesis refinement, and execution planning for sponsors, operators, and portfolio teams.

Watchlist Opportunity

BioDOF strategic investment thesis (under evaluation).

Technology Edge

Supercritical CO2 tissue processing with strong ECM preservation, faster cycle times, and a differentiated quality profile versus legacy chemical wash approaches.

Regulatory and Market Entry

Structured launch path built around Section 361 positioning for selected categories, AATB progression, and staged U.S. commercial deployment.

Scale Plan

Phased execution from rights acquisition and initial channel launch through KOL validation, hospital system expansion, and strategic platform growth.

Engagement Model

From assessment to market traction.

01

Rapid Diagnostic

2-4 week assessment of market, operations, and regulatory realities.

02

Execution Blueprint

30-90 day operating plan with owners, metrics, and risk controls.

03

Pilot and Prove

Controlled deployment to generate adoption data and financial signal.

04

Scale and Institutionalize

Repeatable rollout model, governance cadence, and KPI-driven expansion.

Platform Spotlight

BioDOF U.S. commercialization concept.

Through leadership collaboration with Medici BioStrategy and BioDOF, the team has shaped a North American commercialization thesis around a supercritical CO2 tissue platform with validated implant history and a clear regulatory strategy for disciplined launch and scale.

26,000+

Reported successful implants in referenced program data

51

Top-tier hospitals represented in prior regional deployment

Q2 2026

Target launch window referenced in milestone planning

Leadership

Built by operators with clinical and commercial depth.

All six founding leaders are in the same Executive MBA cohort graduating in May 2026.

Joseph Khouri

Joseph "Joe" Khouri, MD

Chief Executive Officer

Board-certified reconstructive surgeon, Associate Professor, and UH Ventures medical director focused on medtech strategy and commercialization.

David Price

David Price

Chief Operating Officer

Senior operations leader and U.S. military veteran driving systems integration, execution discipline, and EBITDA-focused transformation.

Emmanuel Otomewo

Emmanuel "Manny" Otomewo, MD

Chief Financial Officer

Physician advisor and associate professor focused on quality, safety, reimbursement optimization, and financial stewardship.

Aliaksandr Ramaniuk

Aliaksandr "Alex" Ramaniuk, MD

Chief Technology Officer

Pulmonary and critical care physician-executive and finance-trained strategist leading AI-enabled clinical operations and enterprise transformation.

Vahid Entezari

Vahid Entezari, MD

Chief Transformation & Marketing Officer (CTMO)

Orthopaedic division head and surgeon with deep clinician behavior, medtech differentiation, and platform scalability insight.

Taha Qazi

Taha "Sonny" Qazi, MD

Chief Innovation Officer

Clinician-scientist and strategic advisor with translational research depth and enterprise innovation perspective.

Let's Build The Next Platform

Engage Lakeland Strategic Partners.

For strategic advisory, commercialization, operating transformation, or diligence support, we can start with an executive scoping call.

hello@lakelandstrategicpartners.com